| Sansonno et al.75
|
20 |
All received prior IFN α therapy 80% achieved CR,* with a variety of symptoms Profound B-cell depletion demonstrated with recovery after 6 mos Response maintenance at 12 mos was 75%; relapse rate was 25% at average of 7 mos |
| Lamprecht et al.81
|
1 |
45 y woman with purpura, arthralgia, polyneuropathy, and NHL Prior failed IFN α-2b and RBV and cytoxan therapies Remission induced with 6 rituximab infusions; maintained in remission on PEG-IFN α-2b and RBV for 1 year after |
| Zaja et al.82
|
15 |
12/15 HCV-positive pts Rapid response of purpura in all patients Complete but delayed response in neuropathy 2 CR and 1 PR in NHL Steroid-sparing effect shown 1 patient with acute retinal artery thrombosis after infusion #2 |
| Roccatello et al.83
|
6 |
5 pts with MPGN; all responded Complete reversal of BM abnormalities in 3/3 pts 2 symptomatic relapses >1 yr after rituximab |
| Basse et al.84
|
7 |
All pts post-renal transplant; 5 HCV-positive 2 pts received 4 rituximab infusions and developed disseminated opportunistic infections (1 pt died) 5 pts received 2 rituximab infusions. 2/5 CR; 3/5 improvement with follow-up of 3–19 mos. |
| Quartuccio et al.85
|
5 |
All 5 pts had MPGN and responded 3 relapses at 5–12 mos postrituximab 2 pts responded to maintenance doses of rituximab 1 pt had repeat renal biopsy postrituximab with significant improvement |
